SGLT-2 inhibitors: A new mechanism for glycemic control

Clinical Diabetes

Volumn 32, Issue 1, 2014, Pages 4-11

  Chao, Edward C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EGT0001442; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; IPRAGLIFLOZIN; ISIS 388626; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUSEOGLIFLOZIN; METFORMIN; PHLORIZIN; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; SULFONYLUREA; TOFOGLIFLOZIN; UNCLASSIFIED DRUG;

ARTICLE; ASYMPTOMATIC BACTERIURIA; BALANITIS; BLADDER CANCER; BREAST CANCER; CANDIDIASIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE HOMEOSTASIS; GLUCOSURIA; GLYCEMIC CONTROL; HEMATURIA; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; LIVER INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); URINARY TRACT INFECTION; VULVOVAGINITIS;

EID: 84892518091     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.32.1.4     Document Type: Article

References (78)

1. American Diabetes Association: Standards of medical care in diabetes-2012. Diabetes Care 35 (Suppl. 1):S11-S63, 2012
2. Kaiser N, Leibowitz G, Nesher R: Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 16:5-22, 2003
3. Centers for Disease Control and Prevention: National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, Ga., U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. Available from http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed 13 August 2013
4. Centers for Disease Control and Prevention: Press release: Number of Americans with diabetes projected to double or triple by 2050. Older, more diverse population and longer lifespans contribute to increase. 22 October 2010. Available from http://www.cdc.gov/media/pressrel/2010/r101022.html. Accessed 13 August 2013
5. International Diabetes Federation: IDF Diabetes Atlas. 5th ed. Brussels, Belgium, International Diabetes Federation, 2011. Available from http://www.idforg/diabetesatlas. Accessed 13 August 2013
6. Emerging Risk Factors Collaboration: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215-2222, 2010
7. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
8. Esposito K, Chiodini P, Bellstella G, Maiorino MI, Guigliano D: Proportion of patients at HbA1c target < 7% with 8 classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 14:228-233, 2012
9. Resnick HE, Foster GL, Bardsley J, Ratner RE: Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 29:531-537, 2006
10. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS: Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 122:443-453, 2009
11. DeFronzo RA: Banting lecture: From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-795, 2009
12. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina, DL, Miller CD, Ziemer DC, Barnes CS: Clinical inertia. Ann Intern Med 135:825-834, 2001
13. Grant R, Adams AS, Trinacty CM, Zhang F, Kleinman K, Soumerai SB, Meigs JB, Ross-Degna D: Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 30:807-812, 2007
14. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes. JAMA 287:360-372, 2002
15. Gerich JE: Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27:136-142, 2010
16. DeFronzo RA, Davidson JA, del Prato S: The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 14:5-14, 2012
17. Bergman H, Drury DR: The relationship of kidney function to the glucose utilization of the extra abdominal tissues. Am J Physiol 124:279-284, 1938
18. Gerich JE Meyer C, Woerle HJ, Stumvoll M: Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24:382-391, 2001
19. Mather A, Pollock C: Glucose handling by the kidney. Kidney Int Suppl 120:S1-S6, 2011
20. Wright EM, Loo DD, Hirayama BA: Biology of human sodium glucose transporters. Physiol Rev 91:733-794, 2011
21. Farber SJ, Berger EY, Earle DP: Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30:125-129, 1951
22. Mogensen CE: Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 28:101-109, 1971
23. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J: Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427-3434, 2005
24. Krall LP, Levine R, Barnett D: The history of diabetes. In Joslin's Diabetes Mellitus. 13th ed. Kahn CR, Weir GC, Eds. Philadelphia, Pa., Lea and Febiger, 1994, p. 2
25. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J: Phlorizin: a review. Diabetes Metab Res Rev 21:31-38, 2005
26. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA: Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79:1510-1515, 1987
27. Calado J, Santer R, Rueff J: Effect of kidney disease on glucose handling (including genetic defects). Kidney Int Suppl 120:S7-S13, 2011
28. Santer R, Calado J: Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5:133-141, 2010
29. Hussey EK, Clark RV, Amin DM, Kipnes MS, O'Connor-Semmes RL, O'Driscoll EC, Leong J, Murray SC, Dobbins RL, Layko D, Nunez DJ: Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 50:623-635, 2010
30. Hussey EK, Dobbins RL, Stoltz, RR, Stockman NL, O'Connor-Semmes RL, Kapur A, Murray SC, Layko D, Nunez DJ: Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol 50:636-646, 2010
31. Dobbins RL, O'Connor-Semmes R, Kapur A, Kapitza C, Golor G, Mikoshiba I, Tao W, Hussey EK: Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab 14:15-22, 2012
32. Liu JJ, Lee T, DeFronzo RA: Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61:2199-2204, 2012
33. List JF, Whaley JM: Glucose dynamics and mechanistic implications of SGLT-2 inhibitors in animals and humans. Kidney Int Suppl 120:S20-S27, 2011
34. Foote C, Perkovic V, Neal B: Effects of SGLT-2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 9:117-123, 2012
35. Bailey CJ, Igbal N, T'Joen C, List JF: Dapagliflozin monotherapy in drug-naive patients: a randomised controlled trial of low-dose range. Diabetes Obes Metab 14:951-959, 2012
36. Ferrannini E, Seman L, SeewaldtBecker E, Hantel S, Pinnetti S, Woerle HJ: A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 15:721-728, 2013
37. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF: Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33:2217-2224, 2010
38. Kadowaki T, Ikeda S, Takano Y, Cynshi O, Christ AD, Boerlin V, Beyer U, Beck A: Tofogliflozin, a novel and selective SGLT2 inhibitor improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled on stable metformin or diet and exercise alone [Abstract]. Diabetes 61 (Suppl. 1):A22 (80-OR), 2012
39. Kawano H, Kashiwagi A, Kazuta K, Yoshida S, Ueyama E, Utsuno A: Longterm safety, tolerability and efficacy of ipragliflozin in Japanese patients with type 2 diabetes mellitus: IGNITE [Abstract]. Diabetes 61 (Suppl. 1):A611 (2422-PO), 2012
40. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF: Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66:446-456, 2012
41. Seino Y, Sasaki T, Fukatsu A, Samukawa Y, Sakai S, Watanabe T: Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus [Abstract]. Diabetes 61 (Suppl. 1):A266-A267 (1039-P), 2012
42. Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G: Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15:372-382, 2013
43. List J, Woo V, Morales E, Tang W, Fiedorek FT: Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32:650-657, 2009
44. Woerle H-J, Ferrannini E, Berk A, Manun'Ebo M, Pinnetti S, Broedl UC: Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week openlabel extension study in patients with type 2 diabetes [Abstract]. Diabetes 61 (Suppl. 1A):LB13 (49-LB), 2012
45. Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W: Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter in patients with type 2 diabetes mellitus. Diabetes Technol Ther 13:1219-1227, 2011
46. Polidori D, Zhao Y, Alba M, Ferrannini E: Treatment with canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, for 26 weeks improves indices of beta-cell function (BCF) [Abstract]. Diabetes 61 (Suppl. 1):A265 (1032-P), 2012
47. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:2223-2233, 2010
48. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11:43, 2013
49. Cefalu WT, Leiter LA, Niskanen L, Xie J, Millington D, Canovatchel W, Meininger G: Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin [Abstract]. Diabetes 61 (Suppl. 1A):LB10 (38-LB), 2012
50. Goto K, Kashiwagi A, Kazuta K, Yoshida S, Ueyama E, Utsuno A: Ipragliflozin reduces A1c and body weight in type 2 diabetes patients who have inadequate glycemic control on metformin alone: ILLUMINATE study. Diabetes 61 (Suppl. 1):A269, 2012
51. Nauck MA, del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ: Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin. Diabetes Care 34:2015-2022, 2011
52. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ: Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. Electronically published ahead of print on 1 August 2103 (doi: 10.1111/dom.12185)
53. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W; Canagliflozin DIA 2001 Study Group: Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35:1232-1238, 2012
54. Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S: Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97:1020-1031, 2012
55. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, Kawaguchi M, Canovatchel W, Meininger G: Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. Electronically published ahead of print on 5 April 2013 (doi: 10.2337/dc12-2491)
56. Wilding JP, Mathieu C, Vercruysse F, Usiskin K, Deng L, Canovatchel W: Canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes (T2D) inadequately controlled with metformin (MET) and sulfonylurea (SU) [Abstract]. Diabetes 61 (Suppl. 1):A262 (1022-P), 2012
57. Rosenstock J, Vico M, Wei L, Salsali A, List JF: Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35:1473-1478, 2012
58. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, doubleblind, placebo-controlled trial. Diabetes Obes Metab 13:928-938, 2011
59. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, Schwartz S: Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 14:539-545, 2012
60. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S: Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 156:405-415, 2012
61. Wilding JPH, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT: A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Diabetes Care 32:1656-1662, 2009
62. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M: Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 12:510-516, 2010
63. Hardy E, Salsali A, Hruba V, Mansfield T, Rohwedder K, Wessman C, Sugg JE, Wei L, Ptaszynska A, Parikh SJ: Efficacy increases with increasing baseline HbA1c category with dapagliflozin therapy. Diabetes 61 (Suppl. 1):A23, 2012
64. Veltkamp SA, Van Dijk J, Krauwinkel WJJ, Smulders RA: The effect of renal impairment on the pharmacokinetics and urinary glucose excretion of the SGLT2 inhibitor ASP1941 in type 2 diabetes mellitus patients (Abstract). Diabetes 60 (Suppl. 1):A309 (1127-P), 2011
65. U.S. Food and Drug Administration: FDA briefing document: NDA 202293. Dapagliflozin tablets, 5 and 10 mg, 2011. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/Endo-crinologicandMetabolicDrugsAdvisoryCommittee/ucm262994.pdf. Accessed 21 September 2012
66. Yale J, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G: Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15:463-473, 2013
67. Musso G, Gambino R, Cassader M, Pagano G: A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44:375-393, 2012
68. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 359:1811-1821, 2008
69. Cheeseman C: Solute carrier family 2, member 9 and uric acid homeostasis. Curr Opin Nephrol Hypertens 18:428-432, 2009
70. Veltkamp, SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA: Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin Ther 34:1761-1771, 2012
71. Parikh S, Johnsson K, Ptaszynska A, Schmitz B, Sugg J, List JF: Characterization of urinary tract infection in the setting of pharmacologically induced glucosuria [Abstract]. Diabetologia 54 (Suppl.):A841, 2011
72. Nicolle LE, Capuano G, Ways K, Usisikin K: Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 28:1167-1171, 2012
73. Nyirjesy P, Zhao Y, Ways K, Usiskin K: Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 28:1173-1178, 2012
74. Ferrannini E: Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrol Dial Transplant 25:2041-2043, 2010
75. Ljunggren O, Bolinder J, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S: Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 14:990-999, 2012
76. Bristol-Myers Squibb and AstraZeneca: Background document, dapagliflozin, BMS-512148, NDA 202293, 2011. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262996.pdf. Accessed 9 October 2012
77. European Medicines Agency: Forxiga (dapagliflozin) authorisation details. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002322/human_med_001546.jsp&mid=WC0b01ac058001d124. Accessed 17 April 2013
78. U.S. Food and Drug Administration: News release: FDA approves Invokana to treat type 2 diabetes, 2013. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Accessed 17 April 2013